Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.53 |
| ▸ | PTPRG | P23470 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | PRNP | P04156 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942417 | 0.88 | CCR2 (0.49) | CCR2NR3C2AURKAGSK3AGSK3B | |
| SCHEMBL1940043 | 0.87 | ALDH1A1 (0.54) | CCR2IGF1RKMT2AMEN1L3MBTL1 | |
| SCHEMBL1941172 | 0.86 | PKM (0.52) | CCR2IGF1RSCN9AKMT2AMEN1 | |
| SCHEMBL1941006 | 0.85 | CCR2 (0.52) | CCR2GSK3BIGF1RSCN9AKMT2A | |
| SCHEMBL1941059 | 0.85 | KDR (0.49) | CCR2SCN9AKMT2AMEN1KDR | |
| SCHEMBL1941340 | 0.85 | KDR (0.62) | CCR2PTPRGKMT2AMEN1KDR | |
| SCHEMBL1939963 | 0.83 | CCR2 (0.50) | CCR2PTPRGKMT2AMEN1KDR | |
| SCHEMBL1941635 | 0.82 | KDR (0.46) | CCR2KMT2AMEN1KDRRAB9A | |
| SCHEMBL3927477 | 0.82 | CCR2 (0.46) | CCR2NR3C2AURKAKMT2AMEN1 | |
| SCHEMBL1942415 | 0.82 | CCR2 (0.49) | CCR2NR3C2AURKAGSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | CCR2 21/4885PTPRG 788/4885NR3C2 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.